Previous Article | Next Article ![]()
Infection and Immunity, January 2000, p. 257-263, Vol. 68, No. 1
Department of Bacterial Diseases, Walter Reed
Army Institute of Research, Washington, D.C.
20307-5100,1 and American Registry of
Pathology2 and Department of Infectious
and Parasitic Diseases,3 Armed Forces
Institute of Pathology, Washington, D.C. 20306-6000
Received 10 June 1999/Returned for modification 16 July
1999/Accepted 20 October 1999
Entry of opsonized pathogens into phagocytes may benefit or,
paradoxically, harm the host. Opsonization may trigger antimicrobial mechanisms such as reactive oxygen or nitric oxide (NO) production but
may also provide a safe haven for intracellular replication. Brucellae are natural intramacrophage pathogens of rodents, ruminants, dogs, marine mammals, and humans. We evaluated the role of opsonins in
Brucella-macrophage interactions by challenging cultured
murine peritoneal macrophages with Brucella melitensis 16M
treated with complement- and/or antibody-rich serum. Mouse serum
rich in antibody against Brucella lipopolysaccharide
(LPS) (aLPS) and human complement-rich serum (HCS) each enhanced
the macrophage uptake of brucellae. Combinations of suboptimal
levels of aLPS (0.01%) and HCS (2%) synergistically enhanced uptake.
The intracellular fate of ingested bacteria was evaluated with an
optimal concentration of gentamicin (2 µg/ml) to control
extracellular growth but not kill intracellular bacteria. Bacteria
opsonized with aLPS and/or HCS grew equally well inside macrophages in
the absence of gamma interferon (IFN- Brucella spp., short,
nonmotile, nonsporulating, nonencapsulated, gram-negative aerobic rods,
are important facultative intracellular pathogens of humans and
livestock. Brucella melitensis usually infects
sheep, goats, and camels and is the most pathogenic species for
humans (1). Like other facultative intracellular
pathogenic bacteria (e.g., Francisella tularensis,
Listeria monocytogenes, Mycobacterium spp.,
and Legionella pneumophila), clearance of Brucella infection relies on both cell-mediated immunity
(1, 3, 7, 12, 20, 21, 27, 30, 38) and humoral responses (10, 22, 29, 35). The interplay of these two arms of the immune response, however, is not well understood.
Successful infection of the host by Brucella reflects the
ability of the bacterium to establish itself in an intracellular environment favorable for its replication. The presence of
complement or antibody in the extracellular fluid favors killing
of some Brucella strains (35, 38).
Opsonization by these humoral factors also enhances uptake by
phagocytic cells that shelter the bacteria. The intracellular fate of
brucellae may depend on the bacterial species or the kind of phagocyte
ingesting them. For example, opsonization with complement in vitro
leads to uptake and killing of Brucella abortus by human
neutrophils whereas the more virulent B. melitensis survives
under these conditions (38). Similarly, B. abortus opsonized with antibody containing fresh or heated bovine
serum induces the production of oxidative products in bovine neutrophils (6). Although neutrophils represent an important first line of defense against brucellae, the longer-lived mononuclear phagocyte is the more important effector cell for defense against established infection (1). Bovine blood monocyte-derived
macrophages (MDM) ingest more B. abortus bacteria when
opsonized with complement-rich bovine serum than with serum rich in
both antibody and complement (4), suggesting that complement
plays a more important role than specific antibody in uptake and
killing of B. abortus by these bovine blood MDM.
In macrophage-pathogen interactions, complement receptors (CR) and
complement (2, 3, 27) mediate uptake of intracellular pathogens like L. pneumophila (2, 3, 27),
Mycobacterium tuberculosis (32, 33),
and Leishmania donovani (3). Ligation to CR
does not normally trigger the oxidative burst in phagocytes (33,
36, 37). Consequently, intracellular pathogens gain entry to the
cell without the generation of reactive oxygen species, enhancing their
survival within host cells (27, 32). A number of
investigators (10, 11, 14, 16, 18) have opsonized Brucella with antiserum to ensure the infection of
macrophages during in vitro studies. Gross and associates
(14) recently showed that both nonopsonized and
antibody-opsonized Brucella suis strains induce mRNA for
inducible nitric oxide (NO) synthase (iNOS) in the mouse
macrophage-like J774A.1 cell line. However, only antibody-opsonized
B. suis triggers NO production. Gamma interferon
(IFN- Endogenous IFN- In this report, we demonstrate effective ingestion of virulent B. melitensis 16M by resident mouse peritoneal macrophages in
the presence of immune serum or human complement-rich serum (HCS). Combinations of slightly effective concentrations of
immune serum and HCS are synergistic in this in vitro system.
Once internalized, the brucellae grow well in resting
(nonactivated) macrophages whether or not the bacteria were
previously exposed to opsonins. Activation of macrophages
with IFN- Media.
DME-FBS medium contained 10% fetal bovine serum
(FBS) (Hyclone) and 2 mM L-glutamine in Dulbecco's
modified Eagle's medium (DME) (BioWhittaker, Walkersville, Md.).
DME-FBS-MCSF medium consisted of DME-FBS with 40 ng of
recombinant human macrophage colony-stimulating factor per ml, kindly
provided by Jay Stoudemire, Genetics Institute, Cambridge, Mass.
L-Arginine was present in DME at a concentration of 0.4 mM,
except where otherwise indicated.
HCS.
Fresh normal HCS was obtained from a seronegative (by
tube agglutination test) healthy adult volunteer. Venous blood was
drawn into a Vacutainer and allowed to clot at room temperature for about 30 min. It was then centrifuged for 20 min at 4°C and at 1,880 × g. Serum was aliquoted and stored at Antiserum.
Anti-lipopolysaccharide (LPS) serum (aLPS) was
obtained by immunizing BALB/c mice with a mixture of B. abortus and B. melitensis LPS (10 µg of each
LPS/dose) subcutaneously. Two doses of vaccine were administered 4 weeks apart, and the mice were bled 2 weeks after the second dose. Sera
from 5 mice were pooled. Antibody titers to B. melitensis
LPS, determined by enzyme-linked immunosorbent assay, were 1:6,000.
Bacteria.
For macrophage challenge, 16M was grown in
Brucella broth for 24 h in shaker flasks. Bacteria were
pelleted by centrifugation, washed once in 0.9% NaCl, and resuspended
to approximately 2 × 108 bacteria/ml in 0.9% NaCl.
The actual number of viable organisms was determined in retrospect
through dilution and plating for CFU.
Isolation, purification, and bacterial infection of mouse
peritoneal macrophages.
Peritoneal cells were isolated from 8- to
16-week-old female BALB/c mice (Jackson Laboratories, Bar Harbor,
Maine) by lavage with 10 ml of ice-cold
Ca2+,Mg2+-free Hanks balanced salt solution
(BioWhittaker). The peritoneal cells were pelleted, resuspended in
DME-FBS-MCSF, and plated in 96-well polystyrene microtiter plates
(Costar, Cambridge, Mass.) at 0.125 × 106 macrophages
per well. The cultures were incubated overnight at 37°C and 5%
CO2. The supernatant was aspirated and the adherent macrophage monolayer was washed three times with 37°C DME-FBS and
finally covered with 45 µl of DME-FBS-MCSF, with or without HCS or
aLPS. Five microliters of bacterial suspension giving a multiplicity of
infection (MOI) of 8 was added and cultures were returned to the
incubator for 1 h. The concentrations of serum used in these
experiments did not cause bacterial agglutination by light microscopy
or tube testing. After 1 h at 37°C, the supernatant fluid
containing extracellular bacteria was removed and the monolayer was
washed three times with 100-µl aliquots of DME-FBS. Monolayers were
either lysed to obtain 1-h bacterial counts as described below or
replenished with 200 µl of DME-FBS-MCSF routinely containing gentamicin at a concentration of 2 µg/ml. In some instances, this latter medium was supplemented with 10 U of recombinant murine IFN- Determination of bacterial burden (intracellular CFU) in
macrophages.
At appropriate times of incubation in fresh medium
after the initial 1-h infection period, bacterial burden was determined as follows: Triton X-100 was added directly to the 200-µl culture (final concentration, 0.1%) to lyse the macrophages. The number of CFU
in lysates was determined by serial dilutions and plating on
Brucella agar as previously described (8),
without separation of supernatants from adherent cells. We had
previously determined that, within the short period (10 min) of lysis
under these conditions, the 2 µg of gentamicin/ml present in the
culture medium did not affect the viability of brucellae liberated to
the medium (data not shown).
NO production.
The NO content of culture supernatants was
estimated by analysis of nitrite (product of rapid oxidation of NO in
aqueous solution) with the Griess reagent (13).
Data analysis.
Macrophages were cultured in quadruplicate or
quintuplicate under each experimental condition. CFU and NO analyses
were determined independently for each well, so that each raw data
point represents CFU or NO content from one well. Data are expressed as
means ± standard errors of the mean (SEM) for each treatment
group. The significance of differences between treatment groups was
determined using the two-tailed Student's t test. In some
experiments, percent anti-Brucella activity induced by
IFN- Effect of opsonization on the uptake of B. melitensis
16M by mouse peritoneal macrophages.
Macrophages took up only a
small fraction of unopsonized brucellae. During preliminary
investigations in four different experiments, only 1,253 ± 438 (mean ± SEM) CFU were recovered from adherent cells after
exposure of macrophages to bacteria at an MOI of 8 (i.e., approximately
106 CFU) in the absence of HCS or aLPS. In contrast,
opsonization with HCS profoundly enhanced uptake in a
concentration-dependent manner (Fig. 1A);
2% or more HCS led to uptake above the nonopsonized control level
(Fig. 1A). Heating HCS to 56°C for 30 min completely abolished
enhancement (Fig. 1A). Opsonization of bacteria with aLPS serum from
also enhanced uptake in a dose-related manner. Uptake was maximal at
0019-9567/0/$04.00+0
Effects of Opsonization and Gamma Interferon on
Growth of Brucella melitensis 16M in Mouse Peritoneal
Macrophages In Vitro


![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
). Macrophage activation with
IFN-
inhibited replication of both opsonized and
nonopsonized brucellae but was less effective in inhibiting replication
of nonopsonized bacteria. IFN-
treatment of macrophages with
opsonized or nonopsonized bacteria enhanced NO production,
which was blocked by NG-monomethyl
L-arginine (MMLA), an NO synthesis inhibitor. MMLA also
partially blocked IFN-
-mediated bacterial growth inhibition. These
studies suggest that primary murine macrophages have limited ability to
control infection with B. melitensis, even when activated by IFN-
in the presence of highly opsonic concentrations of antibody and complement. Additional cellular immune responses, e.g., those mediated by cytotoxic T cells, may play more important roles in the
control of murine brucellosis.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
)-induced, NO-mediated bacteriostasis occurs preferentially
if brucellae are opsonized with antibody (14). The
contribution of opsonins to the fate of ingested B. melitensis, however, has not been systematically examined. In
addition, the interplay of opsonins and macrophage-activating factors
in the clearance of brucellae from primary macrophages, rather than
cell lines, is unknown.
(39) and interleukin-12 (40)
can mediate protective immunity to B. abortus
infections in CBA/J mice. Treatment of these mice with
anti-interleukin-12 increases splenic bacterial burden and
reduces NO production by macrophages (40). The
IFN-
-mediated decrease in bacterial burden in antibody-opsonized B. suis-infected J774A.1 cells is at least partly due to NO
(14). In other studies (17), however,
B. abortus is only minimally affected by NO-mediated
antimicrobial activity in proteose-peptone-elicited mouse peritoneal
macrophages. This controversy is reminiscent of the controversies
enshrouding NO dependence in the control of secondary L. monocytogenes infection in CBA/J mice (31) and NO
involvement in macrophage candidacidal potency (34).
leads to NO production and inhibition of bacterial growth.
IFN-
-mediated antibacterial activity is partially inhibited by
addition of NG-monomethyl L-arginine (MMLA).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
70°C
until use (usually within 3 months). Aliquots were thawed and used once.
per ml, with or without 1 mM MMLA, a competitive inhibitor of all three
forms of L-arginine-dependent NO synthase. Cultures were
incubated for 48 h before lysis for determination of bacterial counts. Cultures were inspected by light microscopy before lysis. All
monolayers remained intact and cells appeared healthy throughout the
48-h culture period. In preliminary experiments, recombinant human
macrophage colony-stimulating factor was required for preservation of
the monolayers (data not shown).
was calculated as [CFU (minus IFN-
)
CFU (plus
IFN-
)]/[CFU (minus IFN-
)] × 100.
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
0.1% aLPS (Fig. 1B).

View larger version (37K):
[in a new window]
FIG. 1.
Effects of opsonization with Brucella aLPS or
HCS on uptake of brucellae. Macrophage monolayers were incubated with 8 bacteria per macrophage with or without the indicated opsonins.
Controls received DME-FBS-MCSF medium only. After 1 h, monolayers
were lysed and the number of cell-associated CFU was determined by
serial dilution and agar plating. Data are the mean ± SEM CFU in
each well from at least two replicate determinations and represent one
of three similar experiments.
Synergy of complement and antibody. Combining suboptimal concentrations of HCS (2%) with aLPS (0.01%) had a synergistic effect on bacterial uptake (Fig. 2). There was a 3.2-fold increase in the number of CFU recovered when brucellae were treated with the 2% HCS-plus-0.01% aLPS combination, as compared to the sum of the CFU when bacteria were treated with 2% HCS or 0.01% aLPS alone. At optimal concentrations of either antibody or HCS for infection of macrophages, no synergy between HCS and antibody occurred (data not shown). These observations were consistent with a cooperative antibody and complement-mediated uptake of brucellae at suboptimal levels of either reagent. They further indicated that similar maximal levels of bacterial uptake could be achieved by treatment of bacteria with antibody, complement, or both.
|
Effects of gentamicin on recovery of bacteria from macrophages
during prolonged culture.
Since 16M grows in tissue culture medium
at least as well as it does inside macrophages, analysis of the fate of
intracellular brucellae for more than the short periods of time
required for uptake requires the addition of antibiotics to the medium.
Aminoglycosides have traditionally been used for this purpose, because
they penetrate poorly into cells. If present in medium at high
concentrations, however, gentamicin enters macrophages and kills
intracellular bacteria (9). We therefore determined
concentrations of gentamicin that would inhibit extracellular, but not
intracellular, growth under our culture conditions. Macrophages were
cultured with 16M for 1 h and extracellular bacteria were washed
off as described above. Monolayers were then replenished with 200 µl
of DME-FBS-MCSF containing gentamicin at a concentration of 0, 2, 10, or 100 µg/ml. After 30-min or 24-h incubation, the culture medium was
removed and the monolayers were washed three times before lysing and
plating to determine the number of CFU. Data in Table
1 show that gentamicin at a concentration
of 2 µg/ml was safe for intracellular B. melitensis 16M
during long-term incubation. Gentamicin at 2 µg/ml did not significantly affect the number of CFU/well among cultures incubated for 30 min or 24 h (P = 0.17 and P = 0.55, respectively, with respect to cultures incubated without
antibiotics). In contrast, culture with 10 or 100 µg of gentamicin
per ml led to a significant (P < 0.05 to P < 0.008) dose-related reduction in the number of intracellular
CFU at both 30 min and 24 h (Table 1). This bactericidal effect
was further evidenced over the next day of culture. At 0 and 2 µg of
gentamicin per ml, the number of intracellular bacteria increased by 19 and 27%, respectively, from 30 min to 24 h, while at a
concentration of 10 or 100 µg of gentamicin per ml, the number of
intracellular CFU declined by 45 and 77%, respectively (Table 1).
|
caused a similar
inhibition of replication in cultures treated with all three
antibiotic concentrations. These studies indicated that gentamicin
concentrations between 1 and 4 µg/ml were sufficient to control
extracellular bacterial replication but not so high as to
kill intracellular organisms, even in the presence of IFN-
. For this reason, we performed the rest of our long-term studies with a
concentration of 2 µg of gentamicin per ml to inhibit extracellular bacterial replication.
|
Effects of IFN-
on growth of Brucella in
macrophages.
Antibody and complement (35, 38) kill some
strains of Brucella. For intracellular bacteria, enhanced
ingestion by macrophages may thus provide a safe haven by protecting
the bacteria from complement-mediated extracellular killing. On the
other hand, antibody and/or complement may synergize with intracellular
microbicidal mechanisms to enhance bacterial destruction. To examine
these possibilities, we monitored the growth of nonopsonized and
opsonized brucellae in resting and IFN-
-activated macrophages for
48 h. In four preliminary experiments with 1 µg of gentamicin
per ml and duplicate wells, cultures incubated with IFN-
never
contained fewer brucellae at 22 to 24 h than at 1 h.
Moreover, although IFN-
-treated cultures tended to have fewer
brucellae than cultures incubated with medium alone, this difference
was minimal (data not shown). For this reason, the present
studies were performed under conditions that focused on
IFN-
-mediated inhibition of growth at 48 h. Both opsonized and
nonopsonized bacteria increased in number over this period. In
the results shown in Table 3, 16M
opsonized with aLPS, HCS, or a combination of HCS and aLPS grew about
30-fold more rapidly than nonopsonized 16M in macrophages that had not
been treated with IFN-
. In three additional experiments, growth of
nonopsonized bacteria in the absence of IFN-
ranged from 55- to
149-fold. Bacteria opsonized with HCS with or without aLPS alone grew
27- to 139-fold, while those opsonized with aLPS alone grew 108- to
434-fold. Addition of IFN-
to macrophage cultures immediately after
infection inhibited bacterial growth but did not reduce the number of
CFU below the levels at 1 h. Inhibition occurred regardless of
whether brucellae had previously been opsonized. In the experiment
shown in Table 3, culture with IFN-
led to 53%
anti-Brucella activity for nonopsonized bacteria and 68 to 89% activity for opsonized bacteria. In three additional experiments, IFN-
-mediated anti-Brucella activity ranged from 49 to
75% for nonopsonized organisms and 55 to 87% for opsonized organisms. In each of these experiments, IFN-
-mediated anti-Brucella
activity was always greater for each category of opsonized compared to nonopsonized organisms. The choice of opsonin (either aLPS or HCS alone
or aLPS plus HCS) did not consistently affect the intensity of this
activity (data not shown). By linear regression analysis, fold increase
in bacteria in non-IFN-
-treated cultures did not correlate
(P > 0.1) with percent IFN-
-mediated
anti-Brucella activity over all four experiments
(r = 0.404; t = 1.654; n = 16).
|
The involvement of nitric oxide.
Both NO (14, 17,
40) and reactive oxygen intermediates (17) mediate
macrophage anti-Brucella effects. To examine the role of NO
in the IFN-
-mediated anti-Brucella activity described above, we infected macrophages with opsonized brucellae, treated them
with IFN-
in the presence or absence of MMLA in the presence of 0.8 mM L-arginine (twice the concentration in our standard medium), and determined nitrite levels and the number of bacterial CFU
(Fig. 3). Macrophages cultured without
brucellae or cultured with brucellae but without IFN-
made
0.3
nmol of nitrite/200 µl well (i.e.,
1.5 µM). Addition of IFN-
to macrophages cultured without brucellae did not enhance NO
production, but NO production by macrophages cultured with bacteria and
IFN-
was profoundly enhanced (>10-fold). Addition of MMLA, which
completely abrogated NO production, had inconsistent effects on
IFN-
-mediated anti-Brucella activity (Fig. 3). There was
no difference in anti-Brucella activity in MMLA-treated
cultures compared to untreated cultures in which brucellae had been
opsonized with aLPS plus HCS, but partial MMLA-induced inhibition
occurred in cultures in which brucellae had been opsonized with aLPS or
HCS alone. Similar partial inhibition occurred in two other experiments
(data not shown). These data suggest that anti-Brucella
activity is partly NO-dependent but that NO is of minor importance
under the present culture conditions.
|
| |
DISCUSSION |
|---|
|
|
|---|
These studies show that antibody and complement independently and synergistically enhance the uptake of B. melitensis in nonactivated murine macrophages. Complement-mediated enhanced uptake is consistent with the findings of Young and associates (38). They reported that virulent and attenuated strains of B. abortus 296 and B. melitensis EP were rapidly ingested by human polymorphonuclear leukocytes after opsonization with normal complement-containing serum, whereas their nonopsonized counterparts were not ingested.
Gross and associates (14) have extended these studies to B. suis. They showed that opsonization of B. suis with specific antibody greatly increases the internalization of the bacteria by the J774A.1 macrophage-like cell line. In other studies on the uptake of nontypeable Haemophilus influenzae by human polymorphonuclear leukocytes (24), only additive opsonic effects with immunoglobulin-rich normal human serum in combination with complement-rich guinea pig serum were observed. The lack of synergy between complement and antibody in that study probably reflects the use of rather high levels of immune serum (1% guinea pig serum and 10% immune serum). Jones and Winter (18) demonstrated enhanced phagocytosis by treatment of smooth B. abortus 2308 with antibody. In our experimental system, rough strains are readily ingested by macrophages (M. O. Eze, unpublished observations). Strain 19, a semirough strain, is also more easily ingested than 2308 (18) and its uptake is independent of antibody.
The receptors used for the uptake of nonopsonized brucellae are unknown. Synergy between the receptor for the Fc domain of immunoglobulin G (FcR) and the receptor for iC3b, a cleavage product of C3 (C3bR), for the uptake of opsonized sheep erythrocytes is well described (25). Synergy in the uptake of intracellular pathogens may involve a combination of additional phagocyte receptors which, on binding ligand, almost always trigger internalization (such as FcR and the mannose receptors) and those that sometimes fail to trigger ingestion (e.g., CR) (19, 25, 33). Thus, virulent strains of M. tuberculosis are phagocytosed by the cooperation of CR and mannose receptors on human MDM surfaces, whereas attenuated strains are internalized by the function only of CR (33). Interestingly, the O-polysaccharides of smooth brucellae have an abundance of mannosyl residues (1, 5) but resist phagocytosis in the absence of opsonins.
Treatment of B. abortus with complement-rich serum prior to
exposure to human neutrophils leads to extracellular and
intracellular killing of bacteria, but similar treatment of
B. melitensis does not lead to killing
(38). Cheers and Ho (7) reported an increased uptake of antibody-opsonized L. monocytogenes in mice.
Opsonization with antibody did not alter the growth of this organism
once it was inside the liver and spleen cells. On the other hand,
clearance of Salmonella enterica serovar Typhimurium and
B. abortus early in infection increased with opsonization
with specific antibody. It was therefore concluded that a nonspecific
cellular mechanism was responsible for early enhanced resistance to
each infection (7). Our data show that resident mouse
peritoneal macrophages, like human neutrophils, fail to kill B. melitensis. As shown by others for B. abortus
(16) and B. suis (14),
IFN-
-activated macrophages exerted greater inhibition on the growth
of opsonized brucellae than nonopsonized bacteria. It is possible that
the relative ineffectiveness of IFN-
-treated macrophages against nonopsonized bacteria was due to the reduced uptake of nonopsonized organisms and the consequent failure of the fewer ingested bacteria to
trigger the release of adequate antimicrobial effector molecules. It is
also possible that engagement of macrophage FcR or CR by opsonized
brucellae triggers antimicrobial effector responses.
From their work with scavengers and inhibitors of reactive oxygen
species, Jiang and associates concluded (17) that superoxide (O2
) and hydrogen peroxide
(H2O2) might contribute to control of B. abortus in elicited mouse peritoneal macrophages, whereas NO was
of less importance in the process. For several intracellular pathogens,
a lack of correlation in the effects of varying NO levels (with NO
synthase inhibitors or artificial NO donors) on microbial burden has
led to different conclusions regarding the role of NO as an
antipathogen effector. For example, murine macrophage NO may act alone
or cooperate with other macrophage microbicidal mechanisms to kill
Candida (34). For L. monocytogenes,
murine macrophage NO may play a direct listericidal role in primary
infections but may be of less importance in secondary infections
(31). In contrast to the studies of Jiang et al.
(17), Gross and associates (14) have shown that
NO is involved in the elimination of B. suis from murine
cells, provided that both Brucella antibodies and IFN-
are present. Nonopsonized bacteria did not trigger the production of
iNOS or NO, although they did enhance iNOS mRNA levels. Our data most
closely resemble those of Jiang et al. (17), in that
peritoneal macrophages treated with IFN-
shortly after infection
modestly inhibited the growth of Brucella and the
intracellular growth of bacteria in both IFN-
-treated and control
cells was enhanced by the addition of MMLA. The failure of treatment
with MMLA to completely reverse the anti-Brucella effect of
IFN-
in both of our studies indicates that factors other than NO
must play a predominant role in intramacrophage killing. It is more difficult to compare our data with those of Gross et al.
(14), since they used only J774A.1 cells and B. suis, while we used resident peritoneal cells with B. melitensis. It is possible that B. suis is more
susceptible to NO-mediated killing than B. melitensis or
B. abortus. Alternatively, B. suis may induce
higher levels of NO in IFN-
-treated cells than the other
Brucella species. In our system, the levels of NO induced
were approximately 1/2 of those induced by B. suis in the
studies of Gross et al. (14). The failure of any of these
systems to induce the clearance of bacteria from macrophages may be
related to failure to achieve the consistent levels of NO actually
required to kill Brucella. Strategies that induce more NO
production, or favor cooperation between reactive oxygen and reactive
nitrogen to produce more potent antimicrobial moieties such as
peroxynitrite (15), may remedy this deficiency.
Our culture systems also differ from those of others (10, 11, 14,
16-18) in the concentration of antibiotics used to control the
extracellular growth of Brucella. Gentamicin concentrations of
50 µg/ml were used in these previous studies to induce rapid killing of extracellular brucellae at the end of the initial infection period. These high concentrations were justified because rapidity of
killing by aminoglycosides is related to dose. In standard mean
inhibitory concentration or mean bactericidal concentration assays,
brucellae are sensitive to 1 to 4 µg of gentamicin per ml
(23). These data are consistent with our observations that
1 µg of gentamicin/ml was sufficient to prevent growth of 16M over
48 h. In our system, repeated washing of monolayers after the
initial 1-h period of infection reduces the number of recoverable extracellular bacteria to
100 CFU/well (data not shown). It is possible that the use of high concentrations of antibiotics in previous
studies contributed to the decline in CFU in the first 24 h after
infection of macrophages with opsonized or nonopsonized bacteria
observed by those authors. It is possible that recently ingested
bacteria present in membrane-bound compartments are susceptible to
gentamicin that penetrates macrophages when it is present in culture
fluids at high concentrations (9). After some endosomal maturation has occurred, bacteria may be protected from intramacrophage gentamicin, so growth resumes, even if high aminoglycoside levels are
maintained in the culture medium. Trafficking of
Brucella-containing phagosomes consistent with this
hypothesis has recently been demonstrated in HeLa cells
(28). Whether inclusion of high doses of antibiotics in the
studies cited influences the anti-Brucella activity
attributed to IFN-
is unknown but must be considered in the
interpretation of apparently conflicting results.
These studies are important in light of the consistent observation that
the presence of antibody to Brucella, whether derived by
active or passive immunization, leads to profound
anti-Brucella effects (1, 7, 10, 22, 29, 35) in
vivo. Our data suggest that, even when brucellae are opsonized with
antibody and complement, the IFN-
-mediated activation of resting
macrophages inhibits the intracellular growth of B. melitensis but does not result in the clearance of organisms from
their intracellular niche. These studies support the conclusion that
additional cellular immune responses, e.g., those mediated by cytotoxic
T cells (26), may also play important roles or that
additional signals are provided in vivo to further enhance
macrophage brucellacidal activity. We are currently
examining mechanisms of antibody effects in vivo with a murine
model of intranasal infection with B. melitensis.
| |
ACKNOWLEDGMENTS |
|---|
M.O.E. was supported by a senior resident research associateship from the U.S. National Research Council.
We are grateful to Joseph Thompson for technical assistance.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, D.C. 20307-5100. Phone: (301) 319-9573. Fax: (301) 319-9123. E-mail: david.hoover{at}na.amedd.army.mil.
Present address: Department of Chemistry, University of
Winnipeg, Winnipeg, Manitoba, Canada R3B2E9.
Present address: Hemagen Diagnostics, Inc., Columbia, MD 21045.
§ Present address: Dugway Proving Grounds, Dugway, Utah.
Editor: R. N. Moore
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Baldwin, C. L., and A. J. Winter. 1994. Macrophages and Brucella. Immunol. Ser. 60:363-380[Medline]. |
| 2. | Baumler, A. J., and F. Heffron. 1995. Microbial resistance of macrophage effector functions: strategies for evading microbicidal mechanisms and scavenging nutrients within mononuclear phagocytes, p. 115-131. In J. A. Roth, C. A. Bolin, K. A. Brogden, F. C. Minion, and M. J. Wannemuehler (ed.), Virulence mechanisms of bacterial pathogens, 2nd ed. ASM Press, Washington, D.C. |
| 3. |
Blackwell, J. M.,
R. A. Ezekowitz,
M. B. Roberts,
J. Y. Channon,
R. B. Sim, and S. Gordon.
1985.
Macrophage complement and lectin-like receptors bind Leishmania in the absence of serum.
J. Exp. Med.
162:324-331 |
| 4. | Bounous, D. I., F. M. Enright, K. A. Gossett, and C. M. Berry. 1993. Phagocytosis, killing, and oxidant production by bovine monocyte-derived macrophages upon exposure to Brucella abortus strain 2308. Vet. Immunol. Immunopathol. 37:243-256[CrossRef][Medline]. |
| 5. | Bundle, D. R., J. W. Cherwonogrodzky, M. Caroff, and M. B. Perry. 1987. The lipopolysaccharides of Brucella abortus and B. melitensis. Ann. Inst. Pasteur Microbiol. 138:92-98[CrossRef][Medline]. |
| 6. | Canning, P. C., B. L. Deyoe, and J. A. Roth. 1988. Opsonin-dependent stimulation of bovine neutrophil oxidative metabolism by Brucella abortus. Am. J. Vet. Res. 49:160-163[Medline]. |
| 7. | Cheers, C., and M. Ho. 1983. Resistance and susceptibility of mice to bacterial infection. IV. Functional specificity in natural resistance to facultative intracellular bacteria. J. Reticuloendothel. Soc. 34:299-309[Medline]. |
| 8. | Drazek, E. S., H. S. Houng, R. M. Crawford, T. L. Hadfield, D. L. Hoover, and R. L. Warren. 1995. Deletion of purE attenuates Brucella melitensis 16M for growth in human monocyte-derived macrophages. Infect. Immun. 63:3297-3301[Abstract]. |
| 9. |
Drevets, D. A.,
B. P. Canono,
P. J. Leenen, and P. A. Campbell.
1994.
Gentamicin kills intracellular Listeria monocytogenes.
Infect. Immun.
62:2222-2228 |
| 10. | Elzer, P. H., R. H. Jacobson, S. M. Jones, K. H. Nielsen, J. T. Douglas, and A. J. Winter. 1994. Antibody-mediated protection against Brucella abortus in BALB/c mice at successive periods after infection: variation between virulent strain 2308 and attenuated vaccine strain 19. Immunology 82:651-658[Medline]. |
| 11. | Elzer, P. H., R. W. Phillips, G. T. Robertson, and R. M. Roop, II. 1996. The HtrA stress response protease contributes to resistance of Brucella abortus to killing by murine phagocytes. Infect. Immun. 64:4838-4841[Abstract]. |
| 12. | Fortier, A. H., C. A. Nacy, T. Polsinelli, and N. Bhatnagar. 1995. Francisella tularensis, a model pathogen to study the interactin of facultative intracellular bacteria with phagocytic host cells, p. 115-131. In J. A. Roth, C. A. Bolin, K. A. Brogden, F. C. Minion, and M. J. Wannemuehler (ed.), Virulence mechanisms of bacterial pathogens, 2nd ed. ASM Press, Washington, D.C. |
| 13. |
Fortier, A. H.,
T. Polsinelli,
S. J. Green, and C. A. Nacy.
1992.
Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules.
Infect. Immun.
60:817-825 |
| 14. |
Gross, A.,
S. Spiesser,
A. Terraza,
B. Rouot,
E. Caron, and J. Dornand.
1998.
Expression and bactericidal activity of nitric oxide synthase in Brucella suis-infected murine macrophages.
Infect. Immun.
66:1309-1316 |
| 15. | Ischiropoulos, H., L. Zhu, and J. S. Beckman. 1992. Peroxynitrite formation from macrophage-derived nitric oxide. Arch. Biochem. Biophys. 298:446-451[CrossRef][Medline]. |
| 16. |
Jiang, X., and C. L. Baldwin.
1993.
Effects of cytokines on intracellular growth of Brucella abortus.
Infect. Immun.
61:124-134 |
| 17. | Jiang, X., B. Leonard, R. Benson, and C. L. Baldwin. 1993. Macrophage control of Brucella abortus: role of reactive oxygen intermediates and nitric oxide. Cell. Immunol. 151:309-319[CrossRef][Medline]. |
| 18. |
Jones, S. M., and A. J. Winter.
1992.
Survival of virulent and attenuated strains of Brucella abortus in normal and gamma interferon-activated murine peritoneal macrophages.
Infect. Immun.
60:3011-3014 |
| 19. | Levitz, S. M., and A. Tabuni. 1991. Binding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin. J. Clin. Investig. 87:528-535. |
| 20. | Mackaness, G. B. 1964. The immunological basis of acquired cellular resistance. J. Exp. Med. 120:105-120[Abstract]. |
| 21. | Mackaness, G. B. 1971. Resistance to intracellular infection. J. Infect. Dis. 123:439-445[Medline]. |
| 22. |
Montaraz, J. A., and A. J. Winter.
1986.
Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice.
Infect. Immun.
53:245-251 |
| 23. | Mortensen, J. E., D. G. Moore, J. E. Clarridge, and E. J. Young. 1986. Antimicrobial susceptibility of clinical isolates of Brucella. Diagn. Microbiol. Infect. Dis. 5:163-169[CrossRef][Medline]. |
| 24. |
Musher, D. M.,
M. Hague-Park,
R. E. Baughn,
R. J. Wallace, Jr., and B. Cowley.
1983.
Opsonizing and bactericidal effects of normal human serum on nontypable Haemophilus influenzae.
Infect. Immun.
39:297-304 |
| 25. |
Newman, S. L., and R. B. Johnston, Jr.
1979.
Role of binding through C3b and IgG in polymorphonuclear neutrophil function: studies with trypsin-generated C3b.
J. Immunol.
123:1839-1846 |
| 26. | Oliveira, S. C., and G. A. Splitter. 1995. CD8+ type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I- and class II-deficient mice. Eur. J. Immunol. 25:2551-2557[Medline]. |
| 27. |
Payne, N. R., and M. A. Horwitz.
1987.
Phagocytosis of Legionella pneumophila is mediated by human monocyte complement receptors.
J. Exp. Med.
166:1377-1389 |
| 28. |
Pizarro-Cerda, J.,
S. Meresse,
R. G. Parton,
G. van der Goot,
A. Sola-Landa,
I. Lopez-Goni,
E. Moreno, and J. P. Gorvel.
1998.
Brucella abortus transits through the autophagic pathway and replicates in the endoplasmic reticulum of nonprofessional phagocytes.
Infect. Immun.
66:5711-5724 |
| 29. |
Plommet, M., and A. M. Plommet.
1983.
Immune serum-mediated effects on brucellosis evolution in mice.
Infect. Immun.
41:97-105 |
| 30. |
Price, R. E.,
J. W. Templeton,
R. D. Smith, and L. G. Adams.
1990.
Ability of mononuclear phagocytes from cattle naturally resistant or susceptible to brucellosis to control in vitro intracellular survival of Brucella abortus.
Infect. Immun.
58:879-886 |
| 31. | Samsom, J. N., J. A. Langermans, P. H. Groeneveld, and R. van Furth. 1996. Acquired resistance against a secondary infection with Listeria monocytogenes in mice is not dependent on reactive nitrogen intermediates. Infect. Immun. 64:1197-1202[Abstract]. |
| 32. | Schlesinger, L. S. 1993. Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J. Immunol. 150:2920-2930[Abstract]. |
| 33. | Schlesinger, L. S., C. G. Bellinger-Kawahara, N. R. Payne, and M. A. Horwitz. 1990. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J. Immunol. 144:2771-2780[Abstract]. |
| 34. | Vazquez-Torres, A., J. Jones-Carson, and E. Balish. 1995. Nitric oxide production does not directly increase macrophage candidacidal activity. Infect. Immun. 63:1142-1144[Abstract]. |
| 35. |
Winter, A. J.,
J. R. Duncan,
C. G. Santisteban,
J. T. Douglas, and L. G. Adams.
1989.
Capacity of passively administered antibody to prevent establishment of Brucella abortus infection in mice.
Infect. Immun.
57:3438-3444 |
| 36. |
Wright, S. D., and S. C. Silverstein.
1983.
Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes.
J. Exp. Med.
158:2016-2023 |
| 37. |
Yamamoto, K., and R. B. Johnston, Jr.
1984.
Dissociation of phagocytosis from stimulation of the oxidative metabolic burst in macrophages.
J. Exp. Med.
159:405-416 |
| 38. | Young, E. J., M. Borchert, F. L. Kretzer, and D. M. Musher. 1985. Phagocytosis and killing of Brucella by human polymorphonuclear leukocytes. J. Infect. Dis. 151:682-690[Medline]. |
| 39. |
Zhan, Y., and C. Cheers.
1993.
Endogenous gamma interferon mediates resistance to Brucella abortus infection.
Infect. Immun.
61:4899-4901 |
| 40. | Zhan, Y., and C. Cheers. 1995. Endogenous interleukin-12 is involved in resistance to Brucella abortus infection. Infect. Immun. 63:1387-1390[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»